Another human monoclonal antibody targeting the majority of IFN-α subtypes, as well as IFN-ω, JNJ-55920839,67,69 was well tolerated in healthy adults and SLE patients with mild to moderate disease activity in phase I study,67–70 while an improvement in several disease indexes was recorded.68,70 There are no registered phase II studies for this agent yet. Here, IFNA17 is linked to systemic lupus erythematosus.